• Molecular NameMetyrapone
  • SynonymMepyrapone; Methapyrapone; Methbipyranone; Methopirapone; Methopyrapone; Methopyrinine; Methopyrone; Metroprione; Metyrapon
  • Weight226.279
  • Drugbank_IDDB01011
  • ACS_NO54-36-4
  • Show 3D model
  • LogP (experiment)1.9
  • LogP (predicted, AB/LogP v2.0)1.97
  • pkaN/A
  • LogD (pH=7, predicted)1.97
  • Solubility (experiment)9.99 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.0
  • LogSw (predicted, AB/LogsW2.0)5.53
  • Sw (mg/ml) (predicted, ACD/Labs)2.26
  • No.of HBond Donors0
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds3
  • TPSA42.85
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug used in the diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing's syndrome (hypercortisolism).
  • Absorption_value80.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. The major biotransformation is reduction of the ketone to metyrapol, an active alcohol metabolite. Metyrapone and metyrapol are both conjugated with glucuronide.
  • Half life1.9 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include cardiac arrhythmias, hypotension, dehydration, anxiety, confusion, weakness, impairment of consciousness, nausea, vomiting, epigastric pain, and diarrhea.
  • LD50 (rat)LD50=521 mg/kg
  • LD50 (mouse)N/A